Skip to main content

Table 2 Clinical features of subjects stratified by the median RB1 total area and luminal area

From: Sputum mediator profiling and relationship to airway wall geometry imaging in severe asthma

 

Total

Low total area

High total area

p value

Low luminal area

High luminal area

p value

N

59

30

29

 

30

29

 

Male, n

25

12

13

0.37

12

13

0.37

Current age

49 (2)

53 (2)

45 (2)

0.02

53 (2)

45 (2)

0.024

Age of onset

28 (2.5)

34 (3.5)

21 (3)

0.037

32(3.5)

22 (3)

0.041

BMI, kg/m2

29.8 (0.8)

32.3 (1.2)

27.4(1.1)

0.003

32.6 (1.1)

27.1 (1.1)

0.001

Habitual smokers and ex smokers with >10 py

13

10

3

0.16

9

4

0.3

Pack years history

8 (2.5)

11 (5)

6 (2.5)

0.36

11 (5)

6 (2.5)

0.23

Severe Exacerbations

2

2 (0.3)

3 (0.4)

0.03

2 (0.3)

3 (0.4)

0.03

IgE

153 [97–241]

145 [74–183]

162 [84–313]

0.87

143 [82–325]

167 [76–270]

0.89

ACQ6

2.18 (0.13)

2.2 (0.17)

2.14 (0.23)

0.74

2.21 (0.17)

2.15 (0.23)

0.76

Inhaled Corticosteroid dose

2000 [400–4000]

2000 [400–4000]

2000 [640–4000]

0.28

2000 [400–4000]

2000 [640–4000]

0.43

Subjects taking oral corticosteroids

25

15

10

0.72

15

10

0.72

Daily prednisolone dose, mg

4.5 (0.7)

6 (1.2)

2.5 (0.7)

0.54

5.5 (1.5)

3.5 (0.8)

0.83

Pre Bronchodilator FEV1

2.26 (0.12)

2.24 (0.17)

2.2 (0.16)

0.9

2.18 (0.17)

2.34 (0.15)

0.49

Pre Bronchodilator FEV1% predicted

2.42 (0.12)

2.4 (0.18)

2.4 (0.16)

0.98

2.33 (0.18)

2.5 (0.15)

0.48

BD reversibility, ml

0.23 (0.07)

0.31 (0.14)

0.13 (0.03)

0.23

0.29 (0.13)

0.15 (0.03)

0.36

Pre Bronchodilator FVC

3.26 (0.1)

3.22 (0.21)

3.29 (0.20)

0.87

3.1 (0.22)

3.3 (0.18)

0.39

Pre Bronchodilator FVC

3.35 (0.1)

3.36 (0.21)

3.32 (0.20)

0.88

3.27 (0.21)

3.42 (0.18)

0.61

Pre Bronchodilator FEV1% of predicted

75.2 (3)

76 (4)

74.3 (3.6)

0.79

74.3 (5)

76 (3.4)

0.77

Post Bronchodilator FEV1% of predicted

80.8 (2.9)

80.8 (4)

80.8 (3.4)

0.99

78.4 (5)

83.1(3.2)

0.42

Bronchodilator Reversibility %FEV1

5.9 (0.97)

5.4 (1.4)

6.4 (1.7)

0.58

4.7 (0.8)

7.1 (1.7)

0.22

Pre Bronchodilator FEV1/FVC ratio

69.5 (1.8)

69 (2.6)

69.3 (2.7)

0.82

69.6 (2.4

69.4 (2.5)

0.95

Post Bronchodilator FEV1/FVC ratio

72.1 (1.7)

78 (2.5)

72.8 (2.5)

0.62

70.7 (2.4)

73.4 (2.4)

0.44

Total Cells

0.5 [0.4-0.8]

0.6 [0.3-1.1]

0.5 [0.3-0.8]

0.61

0.6 [0.3-1]

0.5 [0.3-0.8]

0.77

Neutrophils %

58.3 [48–69.5]

55.6 [40.7-76.3]

60 [50.1-72.6]

0.97

56.2 [47–77]

59.9 [49.5-72.5]

0.76

Eosinophils %

2.2 [1.5-3.4]

2.5 [1.3-4.5]

2 [1.1-3.7]

0.43

2.2 [1.1-4.2]

2.2 [1.2-4]

0.80

Bronchiectasis present,%

23 (39)

7(30)

16 (69)

0.02

9 (39)

14 (60)

0.16

Bronchial Wall Thickening present,%

39 (67)

21(53)

18 (46)

0.66

22 (56)

17 (43)

0.22

Lumen area/Body Surface Area (mm2/m2)

5.3 (0.3)

3.4 (0.2)

7.2 (0.42)

0.001

3.2 (0.2)

7.3 (0.4)

0.001

Total area/Body Surface Area (mm2/m2)

17.8 (0.8)

12.7 (0.6)

22.8 (1)

0.001

13.2 (0.8)

22.3 (0.9)

0.001